HC Wainwright Forecasts Stronger Earnings for FibroBiologics

FibroBiologics Inc. (NASDAQ:FBLG) – Stock analysts at HC Wainwright increased their Q4 2025 earnings estimates for FibroBiologics in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their prior estimate of ($0.11). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ FY2026 earnings at ($0.45) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.88) EPS.

A number of other analysts also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a research report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of FibroBiologics in a research note on Monday, November 3rd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

FibroBiologics Price Performance

NASDAQ FBLG opened at $0.35 on Friday. FibroBiologics has a 1-year low of $0.32 and a 1-year high of $3.76. The company has a market capitalization of $18.13 million, a P/E ratio of -0.73 and a beta of -0.72. The business has a 50 day moving average price of $0.49 and a 200 day moving average price of $0.66.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Friday, October 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03).

Institutional Trading of FibroBiologics

A number of large investors have recently made changes to their positions in the stock. Nuveen LLC acquired a new position in FibroBiologics in the 1st quarter valued at about $31,000. Jane Street Group LLC acquired a new stake in shares of FibroBiologics during the 2nd quarter worth about $60,000. Cascade Financial Partners LLC grew its holdings in shares of FibroBiologics by 11.7% during the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after buying an additional 30,500 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of FibroBiologics by 19.6% during the first quarter. Cerity Partners LLC now owns 93,407 shares of the company’s stock worth $84,000 after buying an additional 15,306 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of FibroBiologics in the first quarter valued at approximately $29,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.